Characteristic | N | Overall, N = 1,7371 | A4, N = 4591 | LEARN, N = 3111 | SF, N = 9671 |
|---|---|---|---|---|---|
Baseline Age | 1,737 | 71.31 (4.70) | 71.97 (4.81) | 70.36 (4.31) | 71.30 (4.72) |
Sex | 1,737 | ||||
Female | 1,083 (62.35%) | 291 (63.40%) | 189 (60.77%) | 603 (62.36%) | |
Male | 654 (37.65%) | 168 (36.60%) | 122 (39.23%) | 364 (37.64%) | |
Years of Education | 1,737 | 16.55 (2.75) | 16.56 (2.72) | 16.57 (2.46) | 16.54 (2.86) |
APOEe4 Status | 1,715 | ||||
e4- | 1,116 (65.07%) | 193 (42.05%) | 232 (75.08%) | 691 (72.97%) | |
e4+ | 599 (34.93%) | 266 (57.95%) | 77 (24.92%) | 256 (27.03%) | |
PACC Score | 1,737 | -0.81 (2.33) | -1.15 (2.43) | -0.71 (2.24) | -0.68 (2.31) |
Baseline Amyloid Status | 1,737 | ||||
Ab- | 1,278 (73.58%) | 0 (0.00%) | 311 (100.00%) | 967 (100.00%) | |
Ab+ | 459 (26.42%) | 459 (100.00%) | 0 (0.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 1,737 | 1.09 (0.19) | 1.33 (0.16) | 0.99 (0.07) | 1.01 (0.11) |
Treatment Group | 1,737 | ||||
A4 Placebo | 236 (13.59%) | 236 (51.42%) | 0 (0.00%) | 0 (0.00%) | |
A4 Treated | 223 (12.84%) | 223 (48.58%) | 0 (0.00%) | 0 (0.00%) | |
LEARN/SF | 1,278 (73.58%) | 0 (0.00%) | 311 (100.00%) | 967 (100.00%) | |
1Mean (SD) | |||||
Demographics
PACC Sample
Demographics for participants with at least two PACC visits
Characteristic | N | Overall, N = 7711 | A4, N = 4591 | LEARN, N = 3111 | SF, N = 11 |
|---|---|---|---|---|---|
Baseline Age | 771 | 71.33 (4.68) | 71.97 (4.81) | 70.36 (4.31) | 77.34 (NA) |
Sex | 771 | ||||
Female | 481 (62.39%) | 291 (63.40%) | 189 (60.77%) | 1 (100.00%) | |
Male | 290 (37.61%) | 168 (36.60%) | 122 (39.23%) | 0 (0.00%) | |
Years of Education | 771 | 16.57 (2.61) | 16.56 (2.72) | 16.57 (2.46) | 16.00 (NA) |
APOEe4 Status | 769 | ||||
e4- | 425 (55.27%) | 193 (42.05%) | 232 (75.08%) | 0 (0.00%) | |
e4+ | 344 (44.73%) | 266 (57.95%) | 77 (24.92%) | 1 (100.00%) | |
PACC Score | 771 | -0.97 (2.36) | -1.15 (2.43) | -0.71 (2.24) | 0.25 (NA) |
Baseline Amyloid Status | 771 | ||||
Ab- | 312 (40.47%) | 0 (0.00%) | 311 (100.00%) | 1 (100.00%) | |
Ab+ | 459 (59.53%) | 459 (100.00%) | 0 (0.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 771 | 1.19 (0.21) | 1.33 (0.16) | 0.99 (0.07) | 1.18 (NA) |
Treatment Group | 771 | ||||
A4 Placebo | 236 (30.61%) | 236 (51.42%) | 0 (0.00%) | 0 (0.00%) | |
A4 Treated | 223 (28.92%) | 223 (48.58%) | 0 (0.00%) | 0 (0.00%) | |
LEARN/SF | 312 (40.47%) | 0 (0.00%) | 311 (100.00%) | 1 (100.00%) | |
PACC Timepoints | 771 | 12.07 (4.12) | 12.31 (4.08) | 11.75 (4.13) | 2.00 (NA) |
PACC Years of Follow Up | 745 | 5.27 (2.05) | 5.25 (1.96) | 5.31 (2.16) | 0.33 (NA) |
1Mean (SD) | |||||
Amyloid Sample
Characteristic | N | Overall, N = 1,7371 | A4, N = 4591 | LEARN, N = 3111 | SF, N = 9671 |
|---|---|---|---|---|---|
Baseline Age | 1,737 | 71.31 (4.70) | 71.97 (4.81) | 70.36 (4.31) | 71.30 (4.72) |
Sex | 1,737 | ||||
Female | 1,083 (62.35%) | 291 (63.40%) | 189 (60.77%) | 603 (62.36%) | |
Male | 654 (37.65%) | 168 (36.60%) | 122 (39.23%) | 364 (37.64%) | |
Years of Education | 1,737 | 16.55 (2.75) | 16.56 (2.72) | 16.57 (2.46) | 16.54 (2.86) |
APOEe4 Status | 1,715 | ||||
e4- | 1,116 (65.07%) | 193 (42.05%) | 232 (75.08%) | 691 (72.97%) | |
e4+ | 599 (34.93%) | 266 (57.95%) | 77 (24.92%) | 256 (27.03%) | |
PACC Score | 1,737 | -0.81 (2.33) | -1.15 (2.43) | -0.71 (2.24) | -0.68 (2.31) |
Baseline Amyloid Status | 1,737 | ||||
Ab- | 1,278 (73.58%) | 0 (0.00%) | 311 (100.00%) | 967 (100.00%) | |
Ab+ | 459 (26.42%) | 459 (100.00%) | 0 (0.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 1,737 | 1.09 (0.19) | 1.33 (0.16) | 0.99 (0.07) | 1.01 (0.11) |
Treatment Group | 1,737 | ||||
A4 Placebo | 236 (13.59%) | 236 (51.42%) | 0 (0.00%) | 0 (0.00%) | |
A4 Treated | 223 (12.84%) | 223 (48.58%) | 0 (0.00%) | 0 (0.00%) | |
LEARN/SF | 1,278 (73.58%) | 0 (0.00%) | 311 (100.00%) | 967 (100.00%) | |
1Mean (SD) | |||||
Demographics for participants with at least two amyloid scans
Characteristic | N | Overall, N = 5361 | A4, N = 3671 | LEARN, N = 1691 |
|---|---|---|---|---|
Baseline Age | 536 | 71.17 (4.59) | 71.77 (4.68) | 69.88 (4.13) |
Sex | 536 | |||
Female | 346 (64.55%) | 237 (64.58%) | 109 (64.50%) | |
Male | 190 (35.45%) | 130 (35.42%) | 60 (35.50%) | |
Years of Education | 536 | 16.55 (2.52) | 16.50 (2.63) | 16.65 (2.26) |
APOEe4 Status | 535 | |||
e4- | 283 (52.90%) | 148 (40.33%) | 135 (80.36%) | |
e4+ | 252 (47.10%) | 219 (59.67%) | 33 (19.64%) | |
PACC Score | 536 | -0.84 (2.40) | -1.05 (2.44) | -0.38 (2.26) |
Baseline Amyloid Status | 536 | |||
Ab- | 169 (31.53%) | 0 (0.00%) | 169 (100.00%) | |
Ab+ | 367 (68.47%) | 367 (100.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 536 | 1.23 (0.21) | 1.33 (0.16) | 0.99 (0.07) |
Treatment Group | 536 | |||
A4 Placebo | 189 (35.26%) | 189 (51.50%) | 0 (0.00%) | |
A4 Treated | 178 (33.21%) | 178 (48.50%) | 0 (0.00%) | |
LEARN/SF | 169 (31.53%) | 0 (0.00%) | 169 (100.00%) | |
PACC Timepoints | 536 | 13.94 (2.68) | 13.66 (2.93) | 14.56 (1.90) |
PACC Years of Follow Up | 518 | 6.13 (1.30) | 5.89 (1.40) | 6.70 (0.78) |
1Mean (SD) | ||||
TAU Sample
Characteristic | N | Overall, N = 2441 | A4, N = 1961 | LEARN, N = 461 | SF, N = 21 |
|---|---|---|---|---|---|
Baseline Age | 244 | 71.65 (4.74) | 72.11 (4.64) | 69.47 (4.53) | 77.04 (4.29) |
Sex | 244 | ||||
Female | 153 (62.70%) | 127 (64.80%) | 26 (56.52%) | 0 (0.00%) | |
Male | 91 (37.30%) | 69 (35.20%) | 20 (43.48%) | 2 (100.00%) | |
Years of Education | 244 | 16.34 (2.74) | 16.26 (2.82) | 16.74 (2.39) | 16.00 (0.00) |
APOEe4 Status | 244 | ||||
e4- | 120 (49.18%) | 87 (44.39%) | 33 (71.74%) | 0 (0.00%) | |
e4+ | 124 (50.82%) | 109 (55.61%) | 13 (28.26%) | 2 (100.00%) | |
PACC Score | 244 | -1.06 (2.59) | -1.26 (2.51) | 0.02 (2.47) | -5.74 (4.12) |
Baseline Amyloid Status | 244 | ||||
Ab- | 48 (19.67%) | 0 (0.00%) | 46 (100.00%) | 2 (100.00%) | |
Ab+ | 196 (80.33%) | 196 (100.00%) | 0 (0.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 244 | 1.28 (0.20) | 1.34 (0.16) | 1.00 (0.06) | 1.60 (0.02) |
Treatment Group | 244 | ||||
A4 Placebo | 100 (40.98%) | 100 (51.02%) | 0 (0.00%) | 0 (0.00%) | |
A4 Treated | 96 (39.34%) | 96 (48.98%) | 0 (0.00%) | 0 (0.00%) | |
LEARN/SF | 48 (19.67%) | 0 (0.00%) | 46 (100.00%) | 2 (100.00%) | |
1Mean (SD) | |||||
Demographics for participants with at least two tau scans
Characteristic | N | Overall, N = 2171 | A4, N = 1741 | LEARN, N = 431 |
|---|---|---|---|---|
Baseline Age | 217 | 71.59 (4.68) | 72.10 (4.57) | 69.54 (4.63) |
Sex | 217 | |||
Female | 137 (63.13%) | 112 (64.37%) | 25 (58.14%) | |
Male | 80 (36.87%) | 62 (35.63%) | 18 (41.86%) | |
Years of Education | 217 | 16.35 (2.73) | 16.26 (2.80) | 16.70 (2.43) |
APOEe4 Status | 217 | |||
e4- | 109 (50.23%) | 78 (44.83%) | 31 (72.09%) | |
e4+ | 108 (49.77%) | 96 (55.17%) | 12 (27.91%) | |
PACC Score | 217 | -1.05 (2.57) | -1.30 (2.55) | -0.04 (2.45) |
Baseline Amyloid Status | 217 | |||
Ab- | 43 (19.82%) | 0 (0.00%) | 43 (100.00%) | |
Ab+ | 174 (80.18%) | 174 (100.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 217 | 1.27 (0.20) | 1.34 (0.16) | 1.00 (0.06) |
Treatment Group | 217 | |||
A4 Placebo | 87 (40.09%) | 87 (50.00%) | 0 (0.00%) | |
A4 Treated | 87 (40.09%) | 87 (50.00%) | 0 (0.00%) | |
LEARN/SF | 43 (19.82%) | 0 (0.00%) | 43 (100.00%) | |
PACC Timepoints | 217 | 13.65 (2.63) | 13.79 (2.55) | 13.07 (2.87) |
PACC Years of Follow Up | 208 | 5.97 (1.26) | 5.96 (1.19) | 6.05 (1.56) |
1Mean (SD) | ||||
pTAU Sample
Characteristic | N | Overall, N = 7241 | A4, N = 4451 | LEARN, N = 2791 |
|---|---|---|---|---|
Baseline Age | 724 | 71.29 (4.70) | 71.98 (4.83) | 70.19 (4.27) |
Sex | 724 | |||
Female | 457 (63.12%) | 284 (63.82%) | 173 (62.01%) | |
Male | 267 (36.88%) | 161 (36.18%) | 106 (37.99%) | |
Years of Education | 724 | 16.53 (2.60) | 16.53 (2.71) | 16.53 (2.42) |
APOEe4 Status | 723 | |||
e4- | 398 (55.05%) | 187 (42.02%) | 211 (75.90%) | |
e4+ | 325 (44.95%) | 258 (57.98%) | 67 (24.10%) | |
PACC Score | 724 | -0.92 (2.38) | -1.14 (2.45) | -0.57 (2.23) |
Baseline Amyloid Status | 724 | |||
Ab- | 279 (38.54%) | 0 (0.00%) | 279 (100.00%) | |
Ab+ | 445 (61.46%) | 445 (100.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 724 | 1.20 (0.21) | 1.33 (0.16) | 1.00 (0.07) |
Treatment Group | 724 | |||
A4 Placebo | 228 (31.49%) | 228 (51.24%) | 0 (0.00%) | |
A4 Treated | 217 (29.97%) | 217 (48.76%) | 0 (0.00%) | |
LEARN/SF | 279 (38.54%) | 0 (0.00%) | 279 (100.00%) | |
1Mean (SD) | ||||
Demographics for participants with at least two ptau visits
Characteristic | N | Overall, N = 5981 | A4, N = 4261 | LEARN, N = 1721 |
|---|---|---|---|---|
Baseline Age | 598 | 71.41 (4.72) | 72.03 (4.85) | 69.90 (4.01) |
Sex | 598 | |||
Female | 382 (63.88%) | 272 (63.85%) | 110 (63.95%) | |
Male | 216 (36.12%) | 154 (36.15%) | 62 (36.05%) | |
Years of Education | 598 | 16.58 (2.60) | 16.52 (2.74) | 16.72 (2.24) |
APOEe4 Status | 598 | |||
e4- | 321 (53.68%) | 183 (42.96%) | 138 (80.23%) | |
e4+ | 277 (46.32%) | 243 (57.04%) | 34 (19.77%) | |
PACC Score | 598 | -0.87 (2.42) | -1.11 (2.45) | -0.29 (2.25) |
Baseline Amyloid Status | 598 | |||
Ab- | 172 (28.76%) | 0 (0.00%) | 172 (100.00%) | |
Ab+ | 426 (71.24%) | 426 (100.00%) | 0 (0.00%) | |
Baseline Global Amyloid Burden | 598 | 1.23 (0.21) | 1.33 (0.16) | 0.99 (0.07) |
Treatment Group | 598 | |||
A4 Placebo | 220 (36.79%) | 220 (51.64%) | 0 (0.00%) | |
A4 Treated | 206 (34.45%) | 206 (48.36%) | 0 (0.00%) | |
LEARN/SF | 172 (28.76%) | 0 (0.00%) | 172 (100.00%) | |
PACC Timepoints | 598 | 13.06 (3.54) | 12.58 (3.85) | 14.26 (2.17) |
PACC Years of Follow Up | 580 | 5.69 (1.74) | 5.35 (1.86) | 6.57 (0.95) |
1Mean (SD) | ||||